Analyst
Corporate Update Host
Analyst
Corporate Communications
Head of Investor Relations
Jazz Pharmaceuticals plc (JAZZ)Equibles does not estimate personal net worth.
Get an email with a short summary when Biocryst Pharmaceuticals Inc publishes a filing, an earnings call transcript or a press release.
Get BCRX alertsJohn Bluth is recorded as Analyst at Corporate Update Host, Analyst at Corporate Communications and Head of Investor Relations at Jazz Pharmaceuticals plc (JAZZ). John Bluth has spoken on 11 earnings calls and 1 other investor event across 2 companies, most recently for Jazz Pharmaceuticals plc on November 2, 2026. Those appearances were for Biocryst Pharmaceuticals Inc (BCRX) and Jazz Pharmaceuticals plc (JAZZ). Biocryst Pharmaceuticals Inc is classified in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. Jazz Pharmaceuticals plc is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Biocryst Pharmaceuticals Inc includes Charles Gayer (CEO and Board Member), Charlie Gayer (CEO and Board Member), Vincent J. Milano (Chairman and Board Member) and 7 others.
“Today, JAWS Pharmaceuticals reported its third quarter 2026 financial results. The slide presentation accompanying this webcast is available on the Investor section of our website, along with the press release and quarterly report on Form 10Q for the quarter ended September 30, 2026.”
“And just a quick word to note that Sam and I will be making some forward-looking statements today. So please do refer to the risk factors in our securities filings.”
“Today, Jazz Pharmaceuticals reported its second quarter, 2026 financial results. The slide presentation accompanying this webcast is available on the Investor section of our website, along with the press release and quarterly report on Form 10-2 for the second quarter ended June 30, 2026.”
“Today, Jazz Pharmaceuticals reported its fourth quarter and full year 2025 financial results. The slide presentation accompanying this webcast is available on the Investor Section of our website, along with the press release and annual report on Form 10-K for the fiscal year ended December 31st, 2025.”
“Good morning, and welcome to BioCryst's First Quarter 2025 Corporate Update and Financial Results Conference Call. Today's press release and accompanying slides are available on our website.”
Source not stated
Corporate Update Host
Analyst
Source not stated
Corporate Communications
Analyst
Source not stated
Drug Manufacturers - Specialty & Generic · Healthcare
Biotechnology · Healthcare
Head of Investor Relations
